Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.

Advertisement

Related Content

FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
GSK’s Breo Breathing A Little Easier In Asthma, But More Studies Ahead
Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim
GSK’s Breo Ellipta: FDA Panel To Weigh Large Safety Study For Asthma Claim
Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
COPD Market Snapshot: New Products, Limited Differentiation
Theravance To Split Into A Royalty Play and An R&D Company
For Theravance, A Big Year Gets Off To A Strong Start

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel